Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel
NASDAQ:CGEM

Cullinan Therapeutics Q2 2024 Earnings Report

Cullinan Therapeutics logo
$18.13 -0.25 (-1.36%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$18.16 +0.03 (+0.16%)
As of 07/10/2026 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cullinan Therapeutics EPS Results

Actual EPS
-$0.75
Consensus EPS
-$0.73
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Cullinan Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cullinan Therapeutics Announcement Details

Quarter
Q2 2024
Date
8/8/2024
Time
N/A
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
7:15AM ET

Upcoming Earnings

Cullinan Therapeutics' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Cullinan Therapeutics' Q2 2024 Press ReleasePress Release
(8-K)
Cullinan Therapeutics' Q2 2024 Quarterly reportQuarterly report
(10-Q)

Cullinan Therapeutics Earnings Headlines

Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes
June 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cullinan-therapeutics-cgem-27-1-090613388.html
Cullinan Therapeutics: Heading Toward Paydirt
June 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4914254-cullinan-therapeutics-heading-toward-paydirt
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big Tech and Washington policymakers. It can be trucked to a data center, military base, or industrial site and deliver reliable power for years without grid access. A key government milestone expected this August could bring significant visibility to this space. One small stock sits at the center of it.tc pixel
July 12 at 1:00 AM  |  Monument Traders Alliance (Ad)
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases Transcript
June 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4913841-cullinan-therapeutics-inc-cgem-discusses-promising-clinical-data-for-clnminus-978-and
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases - Slideshow
June 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4913873-cullinan-therapeutics-inc-cgem-discusses-promising-clinical-data-for-clnminus-978-and
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
June 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/10/3309602/0/en/cullinan-therapeutics-shares-new-clinical-data-across-its-portfolio-of-t-cell-engager-programs-targeting-cd19-and-bcma-in-autoimmune-diseases.html
See More Cullinan Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cullinan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cullinan Therapeutics and other key companies, straight to your email.

About Cullinan Therapeutics

Cullinan Therapeutics (NASDAQ:CGEM), a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

View Cullinan Therapeutics Profile
Earnings Tools